MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, DNTH had $42,683K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$42,683K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from public offering
    • Proceeds from maturities of inve...
    • Stock-based compensation expense
    • Others
Negative Cash Flow Breakdown
    • Purchases of investment securiti...
    • Net loss
    • Accounts receivable, net
    • Others

Cash Flow
2025-09-30
2025-06-30
Net loss
-36,765 -61,140
Depreciation expense
27 57
Stock-based compensation expense
5,794 11,021
Accretion of discount on investment securities
2,311 2,997
Amortization of right-of-use operating lease assets
72 175
Gain on investment in former related party
227 27
Receivable from former related party
0 -807
Unbilled receivable from former related party
0 0
Accounts receivable, net
4,961 39
Prepaid expenses and other current assets
35 1,321
Other assets
-89 -476
Accounts payable, accrued expenses and operating lease liabilities
3,004 1,589
Deferred revenue
4,758 -123
Deferred revenue - former related party
0 0
Net cash used in operating activities
-30,555 -51,522
Capital expenditures
5 70
Purchases of investment securities
279,841 100,437
Proceeds from maturities of investment securities
78,571 141,746
Net cash used in investing activities
-201,275 41,239
Proceeds from public offering
272,268 -
Payment of issuance costs in connection with public offering
172 -
Proceeds from exercise of stock options
2,230 599
Proceeds from issuance of common stock under espp
187 129
Proceeds from exercise of pre-funded warrants
0 1
Proceeds from private placement
0 0
Payment of issuance costs in connection with private placement
0 0
Net cash provided by financing activities
274,513 729
Increase/(decrease) in cash, cash equivalents and restricted cash
42,683 -9,554
Cash and cash equivalents at beginning of period
23,022 -
Cash and cash equivalents at end of period
56,151 -
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from publicoffering$272,268K Proceeds from exercise ofstock options$2,230K Proceeds from issuance ofcommon stock under espp$187K Net cash provided byfinancing activities$274,513K Canceled cashflow$172K Increase/(decrease) in cash, cashequivalents and restricted...$42,683K Canceled cashflow$231,830K Payment of issuancecosts in connection...$172K Proceeds from maturitiesof investment...$78,571K Stock-based compensationexpense$5,794K Deferred revenue$4,758K Accounts payable,accrued expenses and...$3,004K Other assets-$89K Amortization of right-of-useoperating lease assets$72K Depreciation expense$27K Net cash used ininvesting activities-$201,275K Net cash used inoperating activities-$30,555K Canceled cashflow$78,571K Canceled cashflow$13,744K Purchases of investmentsecurities$279,841K Net loss-$36,765K Capital expenditures$5K Accounts receivable, net$4,961K Accretion of discount oninvestment securities$2,311K Gain on investment informer related party$227K Prepaid expenses andother current assets$35K

Dianthus Therapeutics, Inc. DE (DNTH)

Dianthus Therapeutics, Inc. DE (DNTH)